Trials / Completed
CompletedNCT00472927
Bioequivalence Study of 3 New Formulations of Premarin/MPA Compared With Premarin/MPA (Prempro)
An Open-Label, Single-Dose, Randomized, 4-Period, Crossover, Bioequivalence Study of Three New Formulations of Premarin 0.45mg/Medroxyprogesterone Acetate (MPA) 1.5mg Compared With a Reference Formulation of Premarin/MPA (PremproTM) 0.45mg/1.5mg in Healthy Postmenopausal Women
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- Female
- Age
- 35 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
To evaluate three new investigational tablet formulations of the Food and Drug Administration (FDA) approved medication Prempro™, Premarin combined with medroxyprogesterone acetate (MPA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Premarin/MPA 0.45 mg/1.5 mg |
Timeline
- Start date
- 2007-05-01
- Completion
- 2007-08-01
- First posted
- 2007-05-14
- Last updated
- 2007-12-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00472927. Inclusion in this directory is not an endorsement.